Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia a: Interim Results from an Open-Label Multicenter Clinical Trial

Robert F. Sidonio, Jr., Christine Knoll, Flora Peyvandi, Oleksandra Stasyshyn, Ali Bulent Antmen, Seoh Leng Yeoh, Darintr Sosothikul, Caterina Maggiore, Werner Engl, Geoffrey Allen, Srilatha Tangada

Blood (2021) 138 (Supplement 1): 3184.

https://doi.org/10.1182/blood-2021-146126

Published: 2021

Journal Articles

Rurioctocog Alfa Pegol Use in Immune Tolerance Induction: Interim Results from an Open-Label Multicenter Clinical Trial in Previously Untreated Patients with Severe Hemophilia a

Robert F. Sidonio, Jr., Alexis A. Thompson, Flora Peyvandi, Canan Albayrak, Seoh Leng Yeoh, Joyce Lam, Caterina Maggiore, Werner Engl, Geoffrey Allen, Srilatha Tangada

Blood (2021) 138 (Supplement 1): 3185.

https://doi.org/10.1182/blood-2021-146143

Published: 2021

Journal Articles

Prophylactic Treatment with Rurioctocog Alfa Pegol Results in a Dose-Dependent Normalization of Biomarkers of Joint Health in Severe Hemophilia a: An Exploratory Analysis from the Propel Study

Tina Manon-Jensen, Srilatha Tangada, Cecilie Bager, Pratima Chowdary, Robert Klamroth, Annette von Drygalski, Jerzy Windyga, Miguel A. Escobar, Peder Frederiksen, Werner Engl, Bruce Ewenstein, Morten Karsdal

Blood (2021) 138 (Supplement 1): 2102.

https://doi.org/10.1182/blood-2021-150139

Published: 2021

Journal Articles

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Robert Klamroth, Jerzy Windyga, Vlad Radulescu, Peter W. Collins, Oleksandra Stasyshyn, Hishamshah Mohd Ibrahim, Werner Engl, Srilatha D. Tangada, William Savage, Bruce Ewenstein

Blood (2021) 137 (13): 1818–1827.

https://doi.org/10.1182/blood.2020005673

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy and Safety Results from a Phase 3b, Open-Label, Multicenter, Continuation Study of Rurioctocog Alfa Pegol for Prophylaxis in Previously Treated Patients with Severe Hemophilia A

Eric S. Mullins, MD, Barbara A Konkle, Catherine E. McGuinn, MD, Werner Engl, PhD CStat, Srilatha D. Tangada, PhD

Blood (2018) 132 (Supplement 1): 2483.

https://doi.org/10.1182/blood-2018-99-110190

Published: 2018

Journal Articles

Evaluation of the Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma (BAX326) in Previously Treated and Naïve Patients with Severe or Moderately Severe Hemophilia B: A Continuation Study

Jerzy Windyga, Oleksandra Stasyshyn, MD PhD, Werner Engl, PhD CStat, Srilatha D. Tangada, PhD

Blood (2018) 132 (Supplement 1): 1197.

https://doi.org/10.1182/blood-2018-99-111295

Published: 2018

Journal Articles

Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis

Kathelijn Fischer, MD PhD MSc, Pratima Chowdary, FRCPath, MRCPath, MRCP, MD, Peter Collins, MD, Amy Cotterill, PhD, Barbara Konkle, MD, Victor S. Blanchette, FRCP, FRCPC, Steven W. Pipe, MD, Martin Wolfsegger, Cstat (RSS), Werner Engl, PhD Cstat, Jimena V Goldstine, PhD, Leonard A. Valentino, MD FAAP, Gerald Spotts, PhD

Blood (2016) 128 (22): 2576.

https://doi.org/10.1182/blood.V128.22.2576.2576

Published: 2016

Journal Articles

Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life in Previously Treated Pediatric Patients with Hemophilia Α: Efficacy of Prophylaxis and Treatment By Time (of Day/of Week) of Occurrence of Bleeding

Eric S. Mullins, MD, Christine M. Knoll, MD, Amy L. Dunn, MD, Werner Engl, PhD Cstat, Marlies Sharkhawy, MA, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 1409.

https://doi.org/10.1182/blood.V128.22.1409.1409

Published: 2016

Journal Articles

Target Joint Bleeding in Pediatric Patients with Hemophilia Α Receiving Twice Weekly Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Amy L. Dunn, MD, Alexis A. Thompson, MD MPH, Werner Engl, PhD Cstat, Marlies Sharkhawy, MA, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 3778.

https://doi.org/10.1182/blood.V128.22.3778.3778

Published: 2016

Journal Articles

Target Joint Status in Patients with Hemophilia a during 18 Consecutive Months of Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Werner Engl, PhD Cstat, Lisa Patrone, PhD, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 2592.

https://doi.org/10.1182/blood.V128.22.2592.2592

Published: 2016

Journal Articles

Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α

Frank Michael Horling, PhD, Peter Allacher, PhD, Herwig Koppensteiner, PhD, Werner Engl, PhD Cstat, Fritz Scheiflinger, PhD, Brigitt E. Abbuehl, MD, Birgit M Reipert, PhD

Blood (2016) 128 (22): 2594.

https://doi.org/10.1182/blood.V128.22.2594.2594

Published: 2016

Journal Articles

An Evaluation of Safety with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of 243 Patients with Hemophilia a

Werner Engl, PhD Cstat, Lisa Patrone, PhD, Dyck-Jones Jacqueline, PhD, Srilatha D. Tangada, PhD, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 3801.

https://doi.org/10.1182/blood.V128.22.3801.3801

Published: 2016

Journal Articles

Characteristics of Patients without Bleeding in a Pivotal Trial of Extended Half-Life, Pegylated, Full-length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia A

Alice D. Ma, MD, Robert Klamroth, Marilyn J. Manco-Johnson, MD, Werner Engl, Jacqueline A Dyck-Jones, PhD, Brigitt E. Abbuehl

Blood (2015) 126 (23): 1105.

https://doi.org/10.1182/blood.V126.23.1105.1105

Published: 2015

Journal Articles

Joint Bleeding Patterns in Patients Treated Prophylactically with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855)

Marilyn J. Manco-Johnson, MD, Alice D. Ma, MD, Robert Klamroth, Werner Engl, Lorena Griparic, PhD, Jacqueline A Dyck-Jones, PhD, Brigitt E. Abbuehl

Blood (2015) 126 (23): 2300.

https://doi.org/10.1182/blood.V126.23.2300.2300

Published: 2015

Journal Articles

An Integrated Analysis of Long Term Safety of an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia a

Pratima Chowdary, Barbara Konkle, MD, Tadashi Matsushita, MD PhD, Werner Engl, Lisa Patrone, Brigitt E. Abbuehl

Blood (2015) 126 (23): 3522.

https://doi.org/10.1182/blood.V126.23.3522.3522

Published: 2015

Journal Articles

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

Barbara A. Konkle, Oleksandra Stasyshyn, Pratima Chowdary, David H. Bevan, Tim Mant, Midori Shima, Werner Engl, Jacqueline Dyck-Jones, Monika Fuerlinger, Lisa Patrone, Bruce Ewenstein, Brigitt Abbuehl

Blood (2015) 126 (9): 1078–1085.

https://doi.org/10.1182/blood-2015-03-630897

Published: 2015

Includes: Supplemental data

Journal Articles

Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial

Pier Mannuccio Mannucci, Christine Kempton, Carolyn Millar, Edward Romond, Amy Shapiro, Ingvild Birschmann, Margaret V. Ragni, Joan Cox Gill, Thynn Thynn Yee, Robert Klamroth, Wing-Yen Wong, Miranda Chapman, Werner Engl, Peter L. Turecek, Tobias M. Suiter, Bruce M. Ewenstein

Blood (2013) 122 (5): 648–657.

https://doi.org/10.1182/blood-2013-01-479527

Published: 2013

Includes: Supplemental data

Journal Articles

Detection of Non Inhibitory Binding Antibodies to Von Willebrand Factor Affecting the Clearance of VWF:Ag in Von Willebrand Disease

Blood (2011) 118 (21): 2275.

https://doi.org/10.1182/blood.V118.21.2275.2275

Published: 2011

Journal Articles

New Early Prophylaxis Regimen That Avoids Immunological Danger Signals Can Reduce Factor Eight (FVIII) Inhibitor Development Independent From Product Type Used.

Guenter K.H. Auerswald, MD, Christoph Bidlingmaier, Werner Engl, Heidi Chehadeh, Birgit M Reipert, PhD, Karin Kurnik, MD

Blood (2009) 114 (22): 221.

https://doi.org/10.1182/blood.V114.22.221.221

Published: 2009

Journal Articles

Efficacy and Safety of a New Intravenous Immunoglobulin in Adult Subjects with Chronic Idiopathic Thrombocytopenic Purpura.

Heinz Leibl, PhD, Gyula Varga, MD, Zuzana Volkova, MD, Zoltan Gasztonyi, MD, Antonin Hlusi, MD, Jiri Mayer, MD, Krzysztof Chojnowski, MD, Hans-Heinrich Wolf, MD, Marlies Sharkhawy, MA, Borislava G. Pavlova, PhD, Karl Birthistle, MD, Werner Engl, PhD, Simone Walter, MS, Hartmut J. Ehrlich, MD

Blood (2005) 106 (11): 3984.

https://doi.org/10.1182/blood.V106.11.3984.3984

Published: 2005

NARROW

Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia a: Interim Results from an Open-Label Multicenter Clinical Trial

Rurioctocog Alfa Pegol Use in Immune Tolerance Induction: Interim Results from an Open-Label Multicenter Clinical Trial in Previously Untreated Patients with Severe Hemophilia a

Prophylactic Treatment with Rurioctocog Alfa Pegol Results in a Dose-Dependent Normalization of Biomarkers of Joint Health in Severe Hemophilia a: An Exploratory Analysis from the Propel Study

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Efficacy and Safety Results from a Phase 3b, Open-Label, Multicenter, Continuation Study of Rurioctocog Alfa Pegol for Prophylaxis in Previously Treated Patients with Severe Hemophilia A

Evaluation of the Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma (BAX326) in Previously Treated and Naïve Patients with Severe or Moderately Severe Hemophilia B: A Continuation Study

Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis

Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life in Previously Treated Pediatric Patients with Hemophilia Α: Efficacy of Prophylaxis and Treatment By Time (of Day/of Week) of Occurrence of Bleeding

Target Joint Bleeding in Pediatric Patients with Hemophilia Α Receiving Twice Weekly Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Target Joint Status in Patients with Hemophilia a during 18 Consecutive Months of Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α

An Evaluation of Safety with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of 243 Patients with Hemophilia a

Characteristics of Patients without Bleeding in a Pivotal Trial of Extended Half-Life, Pegylated, Full-length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia A

Joint Bleeding Patterns in Patients Treated Prophylactically with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855)

An Integrated Analysis of Long Term Safety of an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia a

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial

Detection of Non Inhibitory Binding Antibodies to Von Willebrand Factor Affecting the Clearance of VWF:Ag in Von Willebrand Disease

New Early Prophylaxis Regimen That Avoids Immunological Danger Signals Can Reduce Factor Eight (FVIII) Inhibitor Development Independent From Product Type Used.

Efficacy and Safety of a New Intravenous Immunoglobulin in Adult Subjects with Chronic Idiopathic Thrombocytopenic Purpura.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only